Nasdaq Delists Windtree Following Failed $700M BNB Treasury Pivot

Nasdaq has announced the delisting of Windtree Therapeutics (WINT) stock. This decision follows a month after the company revealed a significant strategic shift involving the allocation of $700 million in BNB holdings to repurchase its shares, aiming to bolster its stock price. However, this measure appears to have fallen short of its intended impact, failing to halt the stock’s decline. Nasdaq’s action highlights concerns regarding Windtree’s ability to meet ongoing listing requirements. Windtree now faces substantial challenges in identifying alternative strategies to restore investor confidence and enhance its financial performance. The company’s future remains uncertain, and it must take decisive actions to avoid further adverse consequences.